Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kreiberg

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Clinical Genitourinary Cancer|October 9, 2018
Quality of Life in Long-Term Testicular Cancer Survivors With Compensated Leydig Cell DysfunctionJulie Wang Skøtt, Jakob Lauritsen, Michael Kreiberg, et al.
Journal of the National Cancer Institute|June 28, 2021
Paternity After Treatment for Testicular Germ Cell Cancer: A Danish Nationwide Population-Based Cohort StudyMikkel Bandak, Allan Jensen, Christian Dehlendorff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2020
Reply to S.C. Clasen et alJakob Lauritsen, Mikkel Bandak, Michael Kreiberg, et al.
European Journal of Applied Physiology|July 14, 2017
Beta<sub>2</sub>-adrenergic stimulation increases energy expenditure at rest, but not during submaximal exercise in active overweight menJohan Onslev, Glenn Jacobson, Christian Narkowicz, et al.
BMC Cancer|July 5, 2017
A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention)Mikkel Bandak, Niels Jørgensen, Anders Juul, et al.
The Journal of Urology|May 7, 2018
Sexual Function in a Nationwide Cohort of 2,260 Survivors of Testicular Cancer after 17 Years of FollowupMikkel Bandak, Jakob Lauritsen, Christoffer Johansen, et al.
Journal of Insurance Medicine (New York, N.Y.)|March 1, 2018
Relapse and Mortality Risk of Stage I Testicular CancerCecilia Florvall, Peder Frederiksen, Jakob Lauritsen, et al.
Acta Oncologica (Stockholm, Sweden)|April 5, 2021
Oncological outcome and complications of post-chemotherapy retroperitoneal surgery in non-seminomatous germ cell tumours - a systematic reviewJosephine J Rosenvilde, Gyrithe L Pedersen, Mikkel Bandak, et al.
European Urology Focus|November 29, 2018
Sexual Function and Quality of Life in a National Cohort of Survivors of Bilateral Testicular CancerMikkel Bandak, Jakob Lauritsen, Christoffer Johansen, et al.
Clinical Genitourinary Cancer|September 6, 2023
Insulin-like Factor 3, Basal and Human Chorionic Gonadotropin-Stimulated Testosterone as Biomarkers to Predict the Effect of Testosterone Replacement in Testicular Cancer Survivors With Mild Leydig Cell InsufficiencyClara Medici, Niels Jørgensen, Anders Juul, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Clinical Genitourinary Cancer|October 9, 2018
Quality of Life in Long-Term Testicular Cancer Survivors With Compensated Leydig Cell DysfunctionJulie Wang Skøtt, Jakob Lauritsen, Michael Kreiberg, et al.
Journal of the National Cancer Institute|June 28, 2021
Paternity After Treatment for Testicular Germ Cell Cancer: A Danish Nationwide Population-Based Cohort StudyMikkel Bandak, Allan Jensen, Christian Dehlendorff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2020
Reply to S.C. Clasen et alJakob Lauritsen, Mikkel Bandak, Michael Kreiberg, et al.
European Journal of Applied Physiology|July 14, 2017
Beta<sub>2</sub>-adrenergic stimulation increases energy expenditure at rest, but not during submaximal exercise in active overweight menJohan Onslev, Glenn Jacobson, Christian Narkowicz, et al.
BMC Cancer|July 5, 2017
A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention)Mikkel Bandak, Niels Jørgensen, Anders Juul, et al.
The Journal of Urology|May 7, 2018
Sexual Function in a Nationwide Cohort of 2,260 Survivors of Testicular Cancer after 17 Years of FollowupMikkel Bandak, Jakob Lauritsen, Christoffer Johansen, et al.
Journal of Insurance Medicine (New York, N.Y.)|March 1, 2018
Relapse and Mortality Risk of Stage I Testicular CancerCecilia Florvall, Peder Frederiksen, Jakob Lauritsen, et al.
Acta Oncologica (Stockholm, Sweden)|April 5, 2021
Oncological outcome and complications of post-chemotherapy retroperitoneal surgery in non-seminomatous germ cell tumours - a systematic reviewJosephine J Rosenvilde, Gyrithe L Pedersen, Mikkel Bandak, et al.
European Urology Focus|November 29, 2018
Sexual Function and Quality of Life in a National Cohort of Survivors of Bilateral Testicular CancerMikkel Bandak, Jakob Lauritsen, Christoffer Johansen, et al.
Clinical Genitourinary Cancer|September 6, 2023
Insulin-like Factor 3, Basal and Human Chorionic Gonadotropin-Stimulated Testosterone as Biomarkers to Predict the Effect of Testosterone Replacement in Testicular Cancer Survivors With Mild Leydig Cell InsufficiencyClara Medici, Niels Jørgensen, Anders Juul, et al.
Pageof 3